Live
- Akali Dal stages statewide protests over ‘tardy’ paddy procurement in Punjab
- Firing on Nandan Kanan Express in Odisha, probe launched
- Indian Army Seizes Massive Cache Of Arms And Ammunition In Manipur Amid Ongoing Violence
- Polling Stations Open Across Eastern And Central US As Voters Head To The Ballots In Historic Election
- Hyatt set to expand brand presence in Nepal with hyatt regency lumbini
- ITC’s Interrobang?! 2024 unleashes a staggering 550+ innovative ideas from 4600+ students across India’s premier Business schools
- Bengal school job case: Partha Chatterjee moves fresh bail plea at special CBI court
- Choose Smarter Financial Choices Over Impulsive Spending This Festive Season – Bandhan Mutual Fund
- Samsung Tops India’s Smartphone Market with 23% Value Share in Q3: Counterpoint Research
- Deloitte India opens entries for Enterprise Growth Awards 2024 to celebrate excellence in regional businesses
USFDA team inspects Dr Reddy’s AP plant
USFDA Team Inspects Dr Reddy’s AP Plant. Dr Reddy\'s Laboratories Limited received inspectional observations from the US Food and Drug Administration (USFDA) for one of its active ingredients(APIs) manufacturing plants located in Srikakulam district in Andhra Pradesh. The observations came after a team of the USFDA visited the site recently.
Hyderabad: Dr Reddy's Laboratories Limited received inspectional observations from the US Food and Drug Administration (USFDA) for one of its active ingredients(APIs) manufacturing plants located in Srikakulam district in Andhra Pradesh. The observations came after a team of the USFDA visited the site recently.
The company confirmed the development while stating that these observations will not impact the normal activity of the plant in any way.
"We have received nine inspectional observations from the USFDA after their visit to our API manufacturing facility in Srikakulam district. We will respond to the agency within stipulated timelines with our remedial plans and start implementing the necessary measures immediately," the company spokesperson said in a statement.
According to the company, these observations are largely related to procedural and other compliances of the plant systems. "At this stage, production continues in the normal course and there is no implication on any activity at the plant," the statement said. These inspectional observations are called '483 observations' related to the deviations noticed in the standard manufacturing practices.
